Early HBOT for reducing RT side-effects – early results of a randomized trial in oropharyngeal and nasopharyngeal cancer


Teguh DN, M.D., Levendag PC, M.D., Ph.D., Noever I, R.T.T., Voet P, R.T.T., Est H van der, R.T.T., Rooij P van, M.Sc., Dumans AG, M.D., D.D.S.,Boer MF de, M.D., Ph.D., Huls MPC van der, M.D.,Sterk W, M.D., PH.D.,Schmitz PIM, Ph.D.




Int. J. Radiation Oncology Biol. Phys., Vol. 75, No. 3, pp. 711–716 (2009)

Type publicatie



Gerandomiseerde trial




with tumor originating from the tonsillar fossa and/or soft palate
(15), base of tongue (1), and nasopharynx (3)


were randomized to receive HBOT or not. HBOT consisted of 30 sessions at 2.5 ATA (15 msw) with oxygen breathing for 90 min daily, 5 days per week, applied shortly after the RT
treatment was completed. As of 2005, all patients received validated questionnaires (i.e., the European Organization for Research and Treatment of Cancer [EORTC] QLQ-C30, EORTC QLQ Head and Neck Cancer Module
(H&N35), Performance Status Scale): before treatment; at the start of RT treatment; after 46 Gy; at the end of RT
treatment; and 2, 4, and 6 weeks and 3, 6, 12, and 18 months after follow-up.


On all QoL items, better scores were obtained in patients treated with hyperbaric oxygen. The difference
between HBOT vs. non-HBOTwas significant for all parameters: EORTC H&N35 Swallowing (p = 0.011), EORTC
H&N35 Dry Mouth (p = 0.009), EORTC H&N35 Sticky Saliva (p = 0.01), PSS Eating in Public (p = 0.027), and Pain
in Mouth (visual analogue scale; p < 0.0001).


Patients randomized for receiving hyperbaric oxygen after the RT had better QoL scores for swallowing, sticky saliva, xerostomia, and pain in mouth.

Externe link

Link naar abstract op PubMed



Laatste wijziging: 10 februari 2016